Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Quick Stats
Mar 31, 202648.6
AI Score
HOLD0.43
Volume Ratio
May 11, 2026
Next Earnings
15
+ve Days (30d)
14
-ve Days (30d)
IMNM Stock Summary
Last updated
IMNM is currently trading at $21.025, positioned above its 200-day moving average of $16.07, indicating a long-term uptrend. The stock has a 52-week range of $5.1501 to $27.65.
Technical Analysis: The 50-day moving average stands at $22.57, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates IMNM at 48.6/100 with a HOLD recommendation.
IMNM Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
IMNM Price vs Max Options Open Interest
IMNM Max Change In Options Open Interest
IMNM Options - Sort by Max open Interest (near term)
31st March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IMNM Daily Out of Money Options - Sort by Max open Interest (near term)
31st March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IMNM Daily In the Money Options - Sort by Max open Interest (near term)
31st March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
IMNM Most Active Options by Volume(near term)
31st March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Immunome, Inc. is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
IMNM Moving Averages Analysis
Immunome, Inc. has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Mar 31, 2026
IMNM (Immunome, Inc.) Simple Moving Averages
Moving Averages are last updated Mar 31, 2026
| Days | MA |
|---|---|
| 10 | 20.31 |
| 20 | 20.73 |
| 30 | 21.13 |
| 50 | 22.57 |
| 100 | 21.02 |
| 200 | 16.07 |
IMNM Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 2.2 billion |
| Earnings/Share ($) | -2.43 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -2.3708 |
| EPS Estimate Next Year ($) | -2.1136 |
| WallStreet Target Price ($) | 35.5385 |
| Most Recent Quarter |